47 rue de Paradis, 75010 Paris,France
01 42 46 50 86
info@vaincrealzheimer.org
ESPACE CHERCHEURS
PRESSE
ESPACE NOTAIRES

FAIRE UN DON
Fondation Vaincre Alzheimer Fondation Vaincre Alzheimer
  • LA FONDATION
    • Notre histoire
    • Nos missions >
      • Financement de la recherche
        • Soutenir la recherche d’excellence
        • Soutenir les jeunes chercheurs
        • Financement du don du cerveau
        • Nos projets financés
      • Soutien au personnel soignant
      • Sensibilisation
    • Notre organisation
    • Nos comptes
    • Nos emplois
    • Nos brochures
  • ALZHEIMER
    • Comprendre la maladie
    • Découverte de la maladie
    • Alzheimer en chiffres
    • Les stades
    • Les symptômes
    • Les causes
    • Le diagnostic
    • Les traitements
    • La forme héréditaire
    • La fin de vie
    • Glossaire
  • MALADIES APPARENTÉES
    • La maladie à Corps de Lewy
    • La démence fronto-temporale
    • La démence vasculaire
  • AVOIR UN PROCHE MALADE
    • La vie au quotidien –
      • Communiquer avec le malade
      • Les repas et refus de manger
      • La toilette du malade
      • Aide à l’habillage
      • Activités et participation aux tâches quotidiennes
    • Les troubles du comportement –
      • Agressivité
      • Troubles du sommeil
      • Déambulation & Fugue
    • Sécuriser le domicile
    • Conduite automobile & Alzheimer
    • Les aidants familiaux –
      • Aidant familial salarié
      • Gestion du stress
      • Contacts utiles
    • Aides matérielles et financières
    • Mesures de protection juridique
    • Expliquer Alzheimer aux enfants
  • PRÉVENTION
    • Comment prévenir ? >
      • Agir sur les facteurs de risque
      • Mémoire et alimentation
      • Travailler sa mémoire
      • Mémoire et activité physique
      • Garder le contact
    • Les études scientifiques
    • La prévention secondaire
  • AGIR
    • Devenir donateur >
      • Impôt sur le revenu
      • IFI
    • Organiser une collecte
    • Devenir ambassadeur
    • Journée mondiale Alzheimer >
      • JMA 2020
    • Giving Tuesday
    • Legs, donations et assurances-vie
    • Partenariat
  • ACTUALITÉS

PROJECTS SUPPORTED FOR 2020

You can read the descriptions and results of each research project on Alzheimer’s disease funded by Fondation Vaincre Alzheimer.

Drapeau anglais sélectionné
Drapeau français

Dr.Bénédicte MANOURY

Institut Necker Enfants Malades – CNRS, University of Paris, Deaprtment of Immunology, Infectiology, Hematology

TLR9-triggered innate immune responses in Alzheimer’s disease pathology

PROJECT SUMMARY

Alongside amyloid-β and Tau, immune responses and chronic inflammation are now recognized as central to Alzheimer’s disease (AD) pathology. Immune activation by aggregated proteins or environmental challenges e.g. infection is orchestrated by specific receptors, such as Toll-like receptors (TLRs) present in immune cells including microglia. The intracellular processes by which TLRs contribute to AD pathology are not known. Our proposal is centered on understanding the complex interaction between peripheral immunity and microglial functions. We will focus specifically on TLR9 signaling as there is evidence supporting the putative role of TLR9 and its activating components in AD pathology.

RELEVANCE OF PROPOSED RESEARCH TO ALZHEIMER’S DISEASE

Our project encompasses novel conceptual framework to understand the complex and contradictory immune responses observed in AD. Systemic inflammation can lead to modifications in microglial responses, which in turn can affect AD pathology. Examination of the cell-specific mechanisms through which AD pathology is modified by generating AD mice inactivated for TLR9 in peripheral cells (dendritic and myeloid cells) as well as in microglia and thorough depth RNA and epigenetic analyses will shed light on complex cross-talk between peripheral immune cells and microglia and will bring in forefront the potential mechanisms by which environmental factors affect AD pathology.

January 1st, 2021 – December 31th, 2022 (2 years)

100 000 €

Dr. Cécile PROUST-LIMA

INSERM, Bordeaux Population Health Research Center

Identifying dementia subphenotypes from trajectories of multimodal biomarkers

PROJECT SUMMARY

Our ID3M project envisions to uncover latent sub-phenotypes in Alzheimer’s Disease and related dementias (ADRD) from the trajectories of multiple biomarkers including fluid markers, brain imaging, and neuropsychology. We will develop for that a robust statistical tool combining machine learning and dynamic modeling which simultaneously analyzes the biomarkers trajectories, identifies subgroups of individuals with distinct evolution patterns, and selects the most relevant biomarkers for endophenotype discrimination. The project will leverage rich data of 5 complementary clinical and population-based cohorts to identify the subtypes and characterize their specific physiopathological pathways.

RELEVANCE OF PROPOSED RESEARCH TO ALZHEIMER’S DISEASE

Many neuropathological processes have been identified in the progression of ADRD including protein accumulation in the brain, regional brain atrophies, or cognitive dysfunction. However, the sequence, shape, and temporality of these alterations are highly heterogeneous, and such temporal and phenotypic heterogeneity constitutes a major impediment to the etiologic understanding of ADRD and their underlying mechanisms, and to an effective and targeted therapeutic research. The project will provide cutting-edge technology for a new understanding of ADRD by unraveling the latent sub-phenotypes from large and rich cohort studies and characterizing their physiopathological pathways.

Avril 1st, 2021 – Mars 31th, 2023 (2 years)

100 000 €

Dr. Frédéric CHECLER

CNRS-UCA, Lab. of Cellular and Molecular biology of normal and pathologcal cerebral aging

Role of C99 oligomerization and its exosomal spread in Alzheimer’s disease

PROJECT SUMMARY

Our recent work showed that exosomes, small endosomal-originating vesicles, purified from Alzheimer disease (AD) models contain the β-secretase-derived APP fragment (APP-CTF), C99, existing as both monomers and oligomers. Here we wish to further characterize C99 oligomerization and to study exosomal spread of toxic C99-containing oligomers. Our study is based mainly on high resolution imaging of both C99-oligomerization and exosomal tracking in cell/organotypic/microfluidic device cultures and in animal brains. To track overall C99, we will generate GFP-fused C99 and use a bimolecular fluorescence complementation (BiFC) approach to visualize C99 neo-oligomerization.

RELEVANCE OF PROPOSED RESEARCH TO ALZHEIMER’S DISEASE

Endolysosomal network (ELN) dysfunction is one of the earliest features of AD and implies all ELN compartments including exosomes. A growing body of evidence shows that this ELN dysfunction is associated with early endolysosomal accumulation of C99 and its levels are consistently increased in AD model-purified exosomes. Our recent study revealed that in these vesicles, C99 can oligomerize alone, or in combination with the α-secretase derived fragment C83, but the role of these oligomers remains unknown. Since exosomes are known to participate to the Prion-like transmission of neurotoxic proteins, a key role in the spread of toxic C99 and or C99/C83 oligomers in AD could be envisioned.

July 1st, 2021 – December 31th, 2024 (3 years)

118 153 €

Dr. Lucile BEN HAIM

CNRS, CEA, Paris-Saclay

Targeting astrocyte Kir4.1 to treat depressive symptoms in Alzheimer’s disease

PROJECT SUMMARY

Depressive symptoms are prevalent in Alzheimer’s disease (AD) patients but their cellular basis remains poorly understood. Recent studies identified astrocyte Kir4.1 as a central regulator of depressive-like symptoms (DLS) in rodent models of depression; but it has never been studied in AD. This project aims at targeting Kir4.1 to rescue DLS in AD mice. I will use viral gene transfer to modulate Kir4.1 in the lateral habenula in APP/PS1dE9 AD mice, which display early DLS. First, I will evaluate the effects on DLS through comprehensive behavioral analysis. Second, I will examine changes in astrocyte transcriptome upon Kir4.1 modulation to identify novel downstream molecular targets.

RELEVANCE OF PROPOSED RESEARCH TO ALZHEIMER’S DISEASE

Depressive symptoms are prevalent in Alzheimer’s disease (AD) patients, especially at the prodromal disease stage. These distressing symptoms accelerate AD progression and are often resistant to conventional antidepressants. Yet, the neurobiological underpinnings of depressive symptoms in AD remain unclear, which impedes the development of alternative therapeutic strategies. This study aims at determining the therapeutic potential of targeting the astrocyte protein Kir4.1 to rescue depressive symptoms in a mouse model of AD and identify drugable downstream targets. Promoting AD patient wellbeing through decreasing depressive symptoms could also improve dementia.

January 1st, 2021 – December 31th, 2022 (2 years)

40 000 €

Dr. Santiago RIVERA

Aix-Marseille Université, Institute of Neuropathophysiology

Unraveling MT5-MMP/APP neuronal subcellular interplay in Alzheimer pathogenesis

PROJECT SUMMARY

Our goal is to better understand the pathogenic interplay between the amyloid precursor protein (APP) and membrane-type 5-matrix metalloproteinase (MT5). We hypothesize that MT5/APP interactions at specific subcellular loci yet to be identified contribute to the early stages of AD. Cell biology, biochemistry, advanced microscopy, and electrophysiology methods will be used in genetically modified murine neurons to address two aims: 1) Decipher the intracellular trafficking and fate of APP and its metabolites in AD neurons upon MT5 modulation. 2) Identify the structural domains of MT5 that affect APP trafficking and amyloidogenesis, and the consequences for synaptic integrity and function.

RELEVANCE OF PROPOSED RESEARCH TO ALZHEIMER’S DISEASE

This proposal aims to decipher novel mechanisms of Alzheimer’s pathogenesis involving the recently discovered APP processing secretase MT5-MMP and its control on the fate of APP or APP metabolites at the subcellular level. We expect to i) generate new concepts in the field related to the proteolytic, and more unusual, non-proteolytic moonlighting actions of MT5-MMP, and ii) contribute to better understand neuronal APP trafficking, still largely unknown despite its pathogenic relevance. Eventually, the project will help us validate MT5-MMP as a new target in AD and lay the foundation for innovative therapeutic strategies targeting MT5-MMP/APP interactions in specific subcellular structures.

January 1st, 2021 – December 31th, 2022 (2 years)

100 000€

Twitter
Facebook

Recevez toutes les informations sur nos subventions, bourses et conférences en souscrivant à notre newsletter.

S’ABONNER

Projets Financés

  • Projets 2020
  • Projets 2019
  • Projets 2018
  • Projets 2017
  • Projets 2016
  • Projets 2015
  • Projets 2014
  • Projets 2013
  • Projets 2012
  • Projets 2011
  • Projets 2010
  • Projets 2009
  • Projets 2008
  • Projets 2007
  • Projets 2006
  • Projets 2005

Espace Chercheur

  • Appel à Candidature
  • DIU MA2
  • Comité Scientifique Européen
  • Projets Financés
  • Bourses de Voyage
  • Bourses de Formation
  • Bourses de M2 Recherche
  • Calendrier des Conférences

S'ABONNER À LA NEWSLETTER
CHERCHEUR
S'INSCRIRE

Fondation Vaincre Alzheimer

Créée en 2005, la Fondation Vaincre Alzheimer est une Fondation Reconnue d'Utilité Publique.
Depuis 2005, la Fondation s’est fixé pour missions le financement de la recherche scientifique de qualité et la sensibilisation du public à travers l’information sur la maladie. Elle soutient également le don de cerveau pour la recherche et la formation des médecins pour une meilleure prise en charge des personnes malades.

Nos coordonnées

Fondation Vaincre Alzheimerinfo@vaincrealzheimer.org0142465086
47 rue de ParadisPARIS75010

Menu

  • Accueil
  • La Fondation Vaincre Alzheimer
  • La maladie d’Alzheimer
  • Les maladies apparentées
  • Avoir un proche malade
  • Agir et faire un don
  • Actualités

Nous contacter

Merci,
Votre message a bien été envoyé.

Envoyer
Catégorie juridique : 9220 – Association déclarée - SIRET : 483 041 315 00043
©Fondation Vaincre Alzheimer 2020 | Tous droits réservés  Crédits  Mentions Légales  Plan du site Politique de confidentialité  Politique des Cookies